NMS-P515

Cat. No.:	HY-128599
CAS No.:	1262395-13-0
Molecular Formula:	$C_{21}H_{29}N_3O_2$
Molecular Weight:	355.47
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 3.33 mg/mL (9.37 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8132 mL	14.0659 mL	28.1318 mL
	5 mM	0.5626 mL	2.8132 mL	5.6264 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a K_d of 16 nM and an IC_{50} of 27 nM (in Hela cells). Anti-tumor activity[1].

IC_{50} & Target		
	PARP-1 16 nM (Kd)	PARP-1 27 nM (IC_{50}, in Hela cells)

In Vivo

NMS-P515 (80 mg/kg, orally daily for 12 days) exhibits potent antitumor activity in mouse models based pancreatic cancer[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Subcutaneously implanted Capan-1 pancreatic (BRCA2-mutated) mouse xenografts[1].
Dosage:	80 mg/kg.

Administration:	Orally, once daily for 12 days.
Result:	Clearly reduced the tumor growth (maximal tumor growth inhibition observed: 48%, maximum body weight loss: 6%).

REFERENCES

[1]. Papeo G, et al. Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515. ACS Med Chem Lett. 2019 Mar 13;10(4):534-538.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA